Exagen is transforming the care continuum for patients affected by chronic autoimmune diseases by enabling timely-differential diagnosis, prognosis, and monitoring while optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products, several of which incorporate their proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology, under the AVISE® brand name.
This page was created by a person asserting to represent this business. This website does not endorse this business or is otherwise affiliated with or endorsed by Exagen Inc..